Open label extension study of lanreotide Autogel 120 mg in patients with non functioning entero-pancreatic endocrine tumour

Update Il y a 4 ans
Reference: EUCTR2008-004019-36

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to assess the long term safety of administration of lanreotide Autogel 120 mg every 28 days in patients with non functioning entero-pancreatic neuro endocrine tumour.


Inclusion criteria

  • Non functioning entero-pancreatic tumour